The company continues to advance high-value next-generation programs: Fabry disease: clinical start anticipated in the second half of 2025; NRAS: clinical start anticipated in the second half of 2025; Ongoing streamlining of the research organization. As of the end of the second quarter of 2024, cash, cash equivalents and investments were approximately $688 million, which the company expects to be sufficient to fund its current operating plan into the second half of 2026, assuming all current programs remain wholly owned and are fully prosecuted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Relay Therapeutics announces interim data for RLY-2608
- Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
- Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024
- Relay Therapeutics price target lowered to $24 from $25 at Oppenheimer
- Relay Therapeutics reports Q2 EPS (69c), consensus (73c)